Physician profile
James E Wallace
NPI 1063464006
$4,563.46
in general payments reported to CMS, 2019-2025
28 companies · $48.38 in 2025
The $48.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $575 · 2021: $1,204 · 2022: $769 · 2025: $48.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $402.89 | 2019-2022 | |
| Novo Nordisk INC | $389.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $339.93 | 2019-2022 | |
| Allergan, INC. | $295.18 | 2019-2020 | |
| Lilly USA, LLC | $280.39 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $231.74 | 2019-2022 | |
| Pfizer INC. | $182.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $178.70 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $153.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.20 | 2019-2022 | |
| Amarin Pharma, INC. | $145.01 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $110.03 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.41 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.05 | 2019-2021 | |
| Abbott Laboratories | $69.63 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.57 | 2019-2021 | |
| Shire North American Group INC | $45.35 | 2019 | |
| Astellas Pharma US INC | $37.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.20 | 2019 | |
| Dexcom, INC. | $19.64 | 2022 | |
| Bausch Health US, LLC | $19.23 | 2022 | |
| Genentech USA, INC. | $19.05 | 2019 | |
| Mylan Specialty L.P. | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.